Details up front: mazdutide · 0.9% sodium chloride.
I would like to understand the steps well enough to explain them to someone else.
I have access to a refrigerator with a logger and a freezer without one, which may be relevant.
Which parts of this are load-bearing and which parts are habit?
0.9 per cent is 9 mg of sodium chloride per millilitre — 0.9 g in 100 mL — which works out at about 154 mmol/L of each ion and is why it is called isotonic. The number that sets a beyond-use date is not the tonicity, though: it is the absence of a preservative. Plain 0.9 per cent sodium chloride for injection is single-use, so a compounded preparation made in it is dated on sterility grounds long before chemistry becomes the limit. Bacteriostatic diluents carry benzyl alcohol and buy the twenty-eight days the convention describes; 9 mg/mL of salt buys none of it. A beyond-use date set on stability data alone, with no sterility argument behind it, is a date about the molecule and not about the vial.
The relevant distinction is between compounding for an individual patient and compounding at scale, which are regulated differently.
Compounding is the preparation of a medicine for an individual patient in response to a prescription, where an approved product is unsuitable. It sits outside the approval framework by design rather than by omission.
Regulators generally prohibit compounding what is essentially a copy of a commercially available product, with a shortage listing being the usual exception that permits it temporarily.
Compounding is defined in regulation as preparation for an individual patient under prescription and is distinguished from manufacturing by scale and by the patient-specific requirement.
The caveat is that the legal and regulatory position differs by jurisdiction and nothing here is legal advice.
Check the beyond-use date and what it was based on.
edited 13 Mar 2026 by tess_amankwah — added the citation requested in comments
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemStart with the regulatory basis, because compounding is permitted under specific conditions and those conditions are the whole subject.
Facility quality varies enormously and is the practical determinant of what you receive. The relevant questions are about sterility assurance, potency testing and beyond-use dating.
Ask for the certificate of analysis on the compounded lot. A serious facility will have one; the request itself is informative.
Prohibitions on compounding essential copies of commercially available products are explicit in the relevant regulatory frameworks, with shortage listings as the usual exception.
Ask which salt form. A different salt is a different active moiety.
Answer first: a compounded preparation is made for an individual under a prescription and is not an approved product, so it carries neither the release testing nor the pharmacovigilance of one.
Additives are the other divergence. Preparations combining an active with vitamins or other agents are not equivalent to the approved product and have not been studied in that combination.
Salt forms matter: a compounded preparation using a different salt from the approved product is not the same active moiety, and that has been the specific object of regulatory warnings.
A compounded preparation is unapproved by definition, which is a statement about the framework rather than about the facility.
Ask for the certificate of analysis on the lot. A serious facility has one.
Answering this needs the jurisdiction, since the framework differs substantially between countries and even between states.
Beyond-use dates on compounded sterile preparations are set by standards that depend on the preparation environment and are much shorter than a manufactured product's shelf life.
Regulatory warnings have specifically addressed salt forms differing from the approved active moiety in this therapeutic area.
Compounded means unapproved by definition. That is structural, not pejorative.
The short version: legitimate under a prescription within defined limits, unapproved by definition, and quality depends entirely on the facility.
A compounded preparation has no marketing authorisation, no batch release by a qualified person and no pharmacovigilance obligation attached to it. That is the structural difference from a licensed product.
Facility quality is the dominant variable and cannot be assessed from a website.
The framework is jurisdiction-specific. Check yours rather than a general answer.
edited 12 May 2026 by triple_agonist_q — removed a claim I could not source
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.